13044 Milano (MI)
Contatto: Silvia Pascale
Ruolo: External Funding, Senior Manager
Telefono: 0039 0161487335
Anno di Fondazione: 1992
Impiegati R&D: 124
Settori di attività: Medical devices / Biotech Healthcare
Medical Device, CarbofilmTM, Single Suture Stentless Valve, High Performance Aortic Valves, Perceval Sutureless, Pericardial Tissue Valves, 3D Motion Annuloplasty Ring, Oxygenator, Heart-lung machine, autotransfusion systems, Heart Failure Management systems, neurostimulation, percutaneous mitral valve repair.
Sorin Group Italia s.r.l., a wholly-owned subsidiary of LivaNova PLC, has Italian premises in Mirandola, Saluggia and Milan.
LivaNova, headquartered in London - UK, is a global medical technology company formed by the merger of Sorin S.p.A., a leader in the treatment of cardiovascular diseases, and Cyberonics, a medical device company with core expertise in neuromodulation.
LivaNova (http://www.livanova.com) transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,000 employees worldwide (1,628 in Italy). With a presence in more than 100 countries, LivaNova operates as two business franchises: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.
As pioneers of the VNS (Vagus Nerve Stimulation) Therapy® system, LivaNova delivers advanced medical device solutions for people affected by drug-resistant epilepsy, treatment-resistant depression and heart failure. Additionally, the Company utilizes hypoglossal nerve stimulation to treat obstructive sleep apnea (OSA).
As a global leader in cardiac surgery, LivaNova state-of-the-art cardiac surgery solutions have contributed to significantly enhance patient outcomes. LivaNova has an established leadership position in heart-lung machines and recognition as the world’s #1 cardiopulmonary bypass company. Today our devices and systems are used in more than 50% of open-heart surgery procedures worldwide. Plus, our innovative advanced circulatory support solutions are designed to provide powerful cardiac and respiratory failure support to patients around the world.
SORIN was founded in the mid-50s (in Saluggia, VC) as a part of joint venture project conducted by two Italian companies, automaker Fiat and an industrial company Montecatini to explore the emerging area of potential applications for nuclear energy (SOcietà Ricerche Impianti Nucleari). During the 1960s, the Company's mission narrowed to focus on medical technology, especially on developing coatings and materials for medical devices such as cardiac pacemakers and heart valves. In the early 90s, Sorin acquired Dideco and Stockert, two internationally recognized producers of life support systems used in Cardiac Surgery, and Bellco, a leading provider of hemodialysis products and services for the treatment of chronic renal failure. In 1999, Sorin purchased COBE cardiovascular, a leading manufacturer of advanced cardiopulmonary and autologous blood processing products.The acquisition in 2003 of Carbomedics, to complete its portfolio of mechanical valve products, and Mitroflow, producer of revolutionary aortic pericardial heart valves, have increased Sorin's position as a major provider of heart valve therapy. Nearly 40 years of real-world experience in valves, development of revolutionary biocompatible materials as well as ideal haemodynamic design, high-tech bioengineering, exclusive technologies and the most stringent quality control represent Sorin Group Italia's distinctive approach to ensure absolute levels of quality and reliability while providing the best solution for healthcare professionals and their patients.